ORIGINAL ARTICLE

Cross-sectional survey of treatment practices for urethritis at pharmacies, private clinics and government health facilities in coastal Kenya: many missed opportunities for HIV prevention

Peter M Mugo,1 Sarah Duncan,2 Samuel W Mwaniki,3 Alexander N Thiongo1, Evanson Gichuru,1 Haile Selassie Okuku,1 Elise M van der Elst,1 Adrian D Smith,4 Susan M Graham,1,5 Eduard J Sanders1,6

ABSTRACT

Background While bacterial sexually transmitted infections (STIs) are important cofactors for HIV transmission, STI control has received little attention in recent years. The aim of this study was to assess STI treatment and HIV testing referral practices among health providers in Kenya.

Methods In 2011 we assessed quality of care management for male urethritis at pharmacies, private clinics and government health facilities in coastal Kenya using simulated visits at pharmacies and interviews at pharmacies and health facilities. Quality was assessed using Ministry of Health guidelines.

Results Twenty (77%) of 26 pharmacies, 20 (91%) of 22 private clinics and all four government facilities in the study area took part. The median (IQR) number of adult urethritis cases per week was 5 (2–10) at pharmacies, 3 (1–3) at private clinics and 5 (2–17) at government facilities. During simulated visits, 10% of pharmacies prescribed recommended antibiotics at recommended dosages and durations and, during interviews, 28% of pharmacies and 27% of health facilities prescribed recommended antibiotics at recommended dosages and durations. Most regimens were quinolone-based. HIV testing was recommended during 10% of simulated visits, 20% of pharmacy interviews and 25% of health facility interviews.

Conclusions In an area of high STI burden, most men with urethritis seek care at pharmacies and private clinics. Most providers do not comply with national guidelines and very few recommend HIV testing. In order to reduce the STI burden and mitigate HIV transmission, there is an urgent need for innovative dissemination of up-to-date guidelines and inclusion of all health providers in HIV/STI programmes.

INTRODUCTION

Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG), the commonest causes of male urethritis, result in considerable morbidity and are important cofactors for HIV-1 transmission.1,2 As sexually transmitted infections (STIs) enhance acquisition and transmission of HIV-1, STI treatment is important in HIV-1 prevention in its own right. Care-seeking for STIs presents an important opportunity to test for HIV-1, which is associated with STIs via sexual behaviour patterns. Thus, in a high HIV-1 prevalence setting such as Kenya, it is essential that people seeking care for STIs receive HIV-1 testing and high-quality STI treatment.

Pharmacies in resource-limited settings are often the first—and sometimes the only—point of contact for patients seeking urgent care owing to greater accessibility and patients’ perception of increased privacy.3,5 Previous studies in sub-Saharan Africa and south-east Asia showed that, while the quality of STI care in pharmacies and other private providers was poor compared with government STI clinics,6–8 targeted interventions resulted in significant improvements.9–11

In Kenya the private health sector remains largely unregulated.12 A 2001 publication reported that the quality of STI care at pharmacies and private clinics was poor relative to government facilities,13 and a more recent study documented suboptimal care at pharmacies.14 There is no current information on how patients seeking care are targeted for HIV/STI prevention. No quality improvement interventions targeting pharmacies and private clinics have been evaluated in Kenya. The purpose of this study was to assess the current STI treatment and HIV testing referral practices in coastal Kenya, identifying potential areas for intervention.

METHODS

Study setting

The study was carried out in August and September 2011 in Mtwapa and Shanzu (total population ~100 000), two townships located 16 km north-east of Mombasa along the principal highway connecting Mombasa to Malindi. The area is home to many bars and nightclubs frequented by male and female sex workers and is popular for beach tourism as well as transient stays by truckers and business people. During a mapping exercise conducted 2 weeks before the study, 22 private clinics, 4 government facilities and 26 private pharmacies were identified and GPS-way points taken (figure 1). In general, health facilities are operated by diploma-level clinical and nursing officers. They provide outpatient services including basic laboratory testing, medication dispensing, family planning, delivery, paediatric vaccinations and growth monitoring. Pharmacies are
small to medium-sized businesses with at least one diploma-level pharmacy technician.

A Kenya Medical Research Institute (KEMRI) clinic in the area recruits at-risk adults, including men having sex with men (MSM) and female sex workers (FSWs), for HIV-1 prevention studies. STI diagnosis and treatment is provided to study participants. A high burden of asymptomatic CT and NG has been documented among MSM recently.

Data collection
We invited all pharmacies and health facilities in the area to participate. Two methods of data collection were used: first we conducted simulated client visits at pharmacies and then, a week later, face-to-face interviews at pharmacies and health facilities. We did not send simulated clients to the health facilities because we felt it would be inappropriate to ask them to undergo physical examinations or laboratory testing. Pharmacies were asked for their consent the week before the simulated visits. We minimised bias by providing limited information on the purpose of the study: ‘the advice and treatment offered to patients with STI symptoms’. Health facilities were asked for their consent just before the interviews to minimise bias.

Simulated client visits
In the first phase we trained four men aged 22–26 years as simulated clients to role play a case of acute uncomplicated male urethritis (figure 2). One simulated visit was made at each pharmacy. We gave simulated clients 200 Kenya shillings (KSh) per visit for purchase of medicines (US$1 ≈ KSh85). Approximately 10–20 min after each visit a brief closed-ended questionnaire (see online supplementary appendix 1) was administered to the simulated clients to collect data on the questions that the
Statements:

“There is a fluid like pus coming from my penis... (thick yellow green discharge) ... I also feel pain when urinating and also itchiness...Since the day before yesterday... (No other problems) ... (No such problem before) ... (Have not seen a doctor yet)... (Had intercourse with someone I met in a club at night... about one week ago... a woman)... (Did not use a condom)... what medicines can I buy for this problem? ... (If I referred) which hospital/ clinic/ doctor should I go to?) ... what is the cost of the medicines? ... i do not have enough money ... Please write down for me the remaining medicines and how much they will cost, so that I can look for money to buy later ...

Notes:

1) Each paragraph in the full script was accompanied with a Kiswahili translation and the client was free to switch between the languages, based on specific needs at each pharmacy.

2) Statements in round brackets were made only in response to questioning by pharmacy staff.

Figure 2 Summarised script for a male urethritis case presented by simulated clients at pharmacies in Mtwapa and Shanzu, Kenya, 2011.

pharmacy staff had asked, medicines dispensed, cost of the medicines and advice given. Visits were unscheduled and they were all completed within 3 days. During a feedback meeting at the end of the study, none of the pharmacies reported being suspicious that the visit was simulated.

Interviews

In the second phase we interviewed one healthcare worker at each participating pharmacy and health facility. The questionnaire included both closed- and open-ended questions (see online supplementary appendices 2 and 3). Data collected included: health facility characteristics; male urethritis cases per week; interviewee characteristics; treatment for uncomplicated acute male urethritis; cost of treatment; interviewees’ awareness of care seeking by FSWs and MSM; and challenges experienced in STI management. The interviews were unscheduled, except at a few very busy pharmacies where there was postponement to an agreed-upon time. The interviews lasted a median of 50 min (range 30–85).

Main study outcome

The main study outcome was the quality of urethritis case management assessed against current Kenyan Ministry of Health guidelines for syndromic STI treatment, which are based on WHO guidelines.18–20 Syndromic STI treatment, an approach developed in the 1990s by the WHO, offers the opportunity to diagnose and treat STIs that cause gonorrhoea or syphilis with antibiotics administered at the point of care.21 The main study outcome was the quality of urethritis case management assessed against current Kenyan Ministry of Health guidelines for syndromic STI treatment, which are based on WHO guidelines.18–20 Syndromic STI treatment, an approach developed in the 1990s by the WHO, offers the opportunity to diagnose and treat STIs that cause gonorrhoea or syphilis with antibiotics administered at the point of care.21 The main study outcome was the quality of urethritis case management assessed against current Kenyan Ministry of Health guidelines for syndromic STI treatment, which are based on WHO guidelines.18–20 Syndromic STI treatment, an approach developed in the 1990s by the WHO, offers the opportunity to diagnose and treat STIs that cause gonorrhoea or syphilis with antibiotics administered at the point of care.21

Data management and analysis

Two investigators separately categorised responses to open-ended questions and differences were reconciled by a third investigator. Data from both phases of the study were double-entered in Questionnaire Development System (Nova, Bethesda, Maryland, USA) and compared for agreement. All discrepancies were reconciled with the source before locking the database.

All statistical analyses were done using Stata (StataCorp, College Station, Texas, USA). Data from each simulated visit or interview were assumed to represent the treatment practices at that pharmacy or health facility. Interviewees who did not state their preferred regimens were excluded from the analyses of regimen compliance and efficacy. We calculated proportions for categorical data and medians or means for continuous or count data. Summary scores for history of present illness and provision of counselling messages were calculated, with one point being awarded for each element. Using a χ² test or Fisher exact test for categorical data and a Student t test or Wilcoxon rank-sum test for continuous or count data, characteristics and outcomes were compared between pharmacies and all health facilities, and between government and private facilities.

RESULTS

Response rate

Twenty (77%) of 26 pharmacies, 20 (91%) of 22 private facilities and all four government facilities in the study area took part. There were no differences in terms of size, location and opening hours between the private pharmacies and facilities that took part and those that did not. The main reason given for declining participation was lack of time.

Characteristics of pharmacies and health facilities

Table 1 details the characteristics of participating pharmacies and health facilities. Individually, government facilities reported seeing more cases of male urethritis per week than private facilities.

SUMMARY

We can summarise the study by stating that the main findings were:

- Most pharmacies and health facilities complied with guidelines for treating male urethritis.
- There was a significant difference in the number of cases seen by pharmacies and health facilities.
- Private facilities saw more cases than government facilities.
- Compliance with guidelines was high in both pharmacies and health facilities.

These findings suggest that syndromic STI management is effective in managing male urethritis in Kenya, but further research is needed to identify areas for improvement.
Taken together, pharmacies, private clinics and government facilities reported seeing about 100, 60 and 20 cases of urethritis per week, respectively. The mean reported proportion of pharmacy clients presenting with prescriptions was 41%. Eight (40%) pharmacies reported having a private room for consultation.

Characteristics of interviewees
Apart from gender, there were no significant differences between private and government facility interviewees (table 2). About 90% of all interviewees reported being aware that some of their clients could be FSWs and about one-third were aware that some of their clients could be MSM.

Treatment strategies
Medicines were dispensed at all simulated visits. When simulated clients said they did not have enough money, 12 (60%) of 20 pharmacies dispensed partial courses of each medicine, four

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Characteristics of pharmacies and health facilities in Mtwapa and Shanzu, coastal Kenya, 2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Characteristic</td>
<td>Pharmacies (N=20)</td>
</tr>
<tr>
<td></td>
<td>N (%) or median (IQR†)</td>
</tr>
<tr>
<td>Total number of staff (including interviewees)‡</td>
<td>2 (1–3)</td>
</tr>
<tr>
<td>Opening hours</td>
<td></td>
</tr>
<tr>
<td>Open 6 days per week (various hours)</td>
<td>20 (100%)</td>
</tr>
<tr>
<td>Open 7 days per week (various hours)</td>
<td>10 (50%)</td>
</tr>
<tr>
<td>Open 7 days per week, 24 h daily</td>
<td>0</td>
</tr>
<tr>
<td>Mean opening hours per day</td>
<td>13 (12–14)</td>
</tr>
<tr>
<td>Patient load</td>
<td></td>
</tr>
<tr>
<td>Total number of clients per day (all ages)</td>
<td>60 (30–100)</td>
</tr>
<tr>
<td>Male urethritis cases per week</td>
<td>5 (2–10)</td>
</tr>
<tr>
<td>Reference materials present</td>
<td></td>
</tr>
<tr>
<td>Formularies (Drug Index, BNF, MIMS Africa)</td>
<td>17 (85%)</td>
</tr>
<tr>
<td>Medical references</td>
<td>6 (30%)</td>
</tr>
<tr>
<td>STI guideline or flow chart</td>
<td>1 (5%)</td>
</tr>
<tr>
<td>Internet access (computer or mobile phone)</td>
<td>15 (75%)</td>
</tr>
<tr>
<td>Services relevant to STI/HIV management</td>
<td></td>
</tr>
<tr>
<td>HIV testing</td>
<td>0</td>
</tr>
<tr>
<td>HIV care services§</td>
<td>0</td>
</tr>
</tbody>
</table>

*Values listed where there is significant difference (p<0.05) between private and government health facilities.
†All figures rounded to zero decimal places.
‡This includes both staff with healthcare training (medical, nursing, laboratory, pharmacy) and those with other qualifications.
§HIV care services include post-exposure prophylaxis, prevention of mother-to-child transmission and antiretroviral therapy.

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Characteristics of health workers interviewed during a study of treatment practices for urethritis in Mtwapa and Shanzu, coastal Kenya, 2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Characteristic</td>
<td>Pharmacies (N=20)</td>
</tr>
<tr>
<td></td>
<td>N (%) or median (IQR*)</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>10 (50%)</td>
</tr>
<tr>
<td>Women</td>
<td>10 (50%)</td>
</tr>
<tr>
<td>Age (years)</td>
<td>28 (25–31)</td>
</tr>
<tr>
<td>Highest level of health training attained†</td>
<td></td>
</tr>
<tr>
<td>Certificate</td>
<td>5 (26%)</td>
</tr>
<tr>
<td>Diploma and higher diploma</td>
<td>13 (68%)</td>
</tr>
<tr>
<td>Bachelor’s degree</td>
<td>1 (5%)</td>
</tr>
<tr>
<td>Master’s degree</td>
<td>0</td>
</tr>
<tr>
<td>Work experience (years)</td>
<td>4 (2–7)</td>
</tr>
<tr>
<td>Membership in a professional association</td>
<td>3 (15%)</td>
</tr>
<tr>
<td>Ever attended an in-service course on STI/HIV management</td>
<td>2 (10%)</td>
</tr>
<tr>
<td>Duration of in-service course (days)</td>
<td>5 (3–7)</td>
</tr>
<tr>
<td>Duration since the last course (years)</td>
<td>6 (2–10)</td>
</tr>
</tbody>
</table>

*All figures rounded to zero decimal places.
†Nineteen (95%) of 20 pharmacy interviewees had pharmacy certification (one had not completed training; n=19). Health facility interviewees had training in either medicine (62%) or nursing (38%).
IQR, interquartile range.
(20%) dispensed fewer medicines and four (20%) asked the client to come back with adequate funds.

During the interviews, when asked how they would manage an uncomplicated acute male urethritis case, 16 (80%) of 20 interviewees at pharmacies said they would dispense medicines, two said they would dispense some medicines and then refer, and two said they would only refer. At health facilities, 17 (71%) of 24 interviewees said they would treat based on symptoms and signs and seven (29%) said they would treat based on laboratory results (ie, aetiologically). Five interviewees in the latter group stated the medications they would use for each suspected agent and were therefore included in the analysis of regimen compliance and efficacy.

**History of present illness**
Health facilities scored higher than pharmacies in history-taking (2.1 vs 1.6, p=0.03), mainly due to a difference in asking about recent sexual exposure (table 3).

**Medication regimen compliance with guidelines and potential treatment efficacy**

**Simulated client visits**
While 16 (80%) of 20 pharmacies dispensed compliant antibiotics for NG (norfloxacin or ciprofloxacin), only 45% were at the recommended single dose (table 3); the rest were longer courses, including one 14-day course. With respect to CT treatment, while 85% of pharmacies dispensed a compliant antibiotic, only 10% were at the recommended dosage and duration (65% dispensed too few doses and 15% dispensed excessive doses). Overall, 25% of pharmacies dispensed efficacious CT regimens (four doxycycline-based, one azithromycin-based), but none dispensed an efficacious NG regimen.

Interviews at pharmacies
Fourteen (78%) of 18 pharmacies reported that they would prescribe a quinolone, 56% at the recommended dosage, and the rest would prescribe longer courses. Overall, eight (44%) would prescribe efficacious CT regimens (five doxycycline-based, two azithromycin-based, one based on both antibiotics) but none would have prescribed an efficacious NG regimen.

**Interviews at health facilities**
There were no significant differences in regimen compliance or potential treatment efficacy between private and government health facilities. Sixteen (73%) of 22 health facilities would prescribe compliant NG antibiotics (11 quinolones only; two quinolone plus ceftriaxone; one ceftriaxone only; one amoxicillin only; and one spectinomycin only). However, only 36% stated the right dosage. Overall, 36% would prescribe efficacious CT regimens (seven doxycycline-based, one azithromycin-based), 14% would prescribe efficacious NG regimens (all ceftriaxone-based) and 9% would effectively treat both agents.

**Provision of counselling messages**
Less than one-quarter of interviewees at pharmacies and private clinics and three-quarters at government facilities said they would recommend HIV-1 testing (table 3).

**Cost of treatment**
The median (IQR) cost of medicines dispensed during simulated visits was KSh350 (KSh175–623). During interviews, all pharmacies reported that consultation and dispensing were free of charge; the median (IQR) medication cost was KSh255 (KSh200–410). The median (IQR) consultation fee at health facilities was KSh100 (KSh20–200), KSh150 (KSh0–500) at private clinics and KSh20 (KSh10–20) at government facilities.

### Table 3 Quality of male urethritis case management at pharmacies and health facilities in Mtwapa and Shanzu, Kenya, 2011

<table>
<thead>
<tr>
<th>Quality elements assessed</th>
<th>Simulated visits</th>
<th>Interviews</th>
<th>Private health facilities (N=20)</th>
<th>Government health facilities (N=4)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pharmacies (N=20)</td>
<td>Pharmacies (n=20)</td>
<td>Private health facilities (N=20)</td>
<td>Government health facilities (N=4)</td>
</tr>
<tr>
<td>History of present illness (HPI)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nature and duration of symptoms</td>
<td>20 (100%)</td>
<td>18 (90%)</td>
<td>16 (80%)</td>
<td>4 (100%)</td>
</tr>
<tr>
<td>Recent sexual exposure</td>
<td>15 (75%)</td>
<td>9 (45%)</td>
<td>17 (85%)</td>
<td>1 (25%)*</td>
</tr>
<tr>
<td>Previous care-seeking for current illness</td>
<td>1 (5%)</td>
<td>6 (30%)</td>
<td>10 (50%)</td>
<td>3 (75%)*</td>
</tr>
<tr>
<td>Summary HPI score (maximum 3)</td>
<td>2 (0.5)</td>
<td>1.65 (0.6)</td>
<td>2.2 (0.8)</td>
<td>2.0 (0.8)</td>
</tr>
<tr>
<td>Medication regimen compliance†‡§</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Compliant regimen for gonorrhoea (right dosage and duration)</td>
<td>9 (45%)</td>
<td>10 (56%)</td>
<td>7 (39%)</td>
<td>1 (25%)</td>
</tr>
<tr>
<td>Compliant regimen for Chlamydia (right dosage and duration)</td>
<td>2 (10%)</td>
<td>5 (28%)</td>
<td>5 (28%)</td>
<td>2 (50%)</td>
</tr>
<tr>
<td>Compliant regimens for both gonorrhoea and Chlamydia (right dosage and duration)</td>
<td>2 (10%)</td>
<td>5 (28%)</td>
<td>5 (28%)</td>
<td>1 (25%)</td>
</tr>
<tr>
<td>Potential treatment efficacy for both gonorrhoea and Chlamydia†</td>
<td>0</td>
<td>0</td>
<td>2 (11%)</td>
<td>0</td>
</tr>
<tr>
<td>Provision of counselling messages</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Get an HIV test</td>
<td>2 (10%)</td>
<td>4 (20%)</td>
<td>3 (15%)</td>
<td>3 (75%)*</td>
</tr>
<tr>
<td>Use condoms consistently</td>
<td>12 (60%)</td>
<td>9 (45%)</td>
<td>13 (65%)</td>
<td>3 (75%)</td>
</tr>
<tr>
<td>Get partner treated</td>
<td>13 (65%)</td>
<td>17 (85%)</td>
<td>16 (80%)</td>
<td>4 (100%)</td>
</tr>
<tr>
<td>Adhere to the full course of treatment</td>
<td>19 (95%)</td>
<td>5 (25%)</td>
<td>10 (50%)</td>
<td>1 (25%)</td>
</tr>
<tr>
<td>Summary counselling score (maximum 4)</td>
<td>2.3 (1.3)</td>
<td>1.8 (0.9)</td>
<td>2.1 (0.9)</td>
<td>2.8 (1.0)</td>
</tr>
</tbody>
</table>

*Significant difference (p<0.05) between private and government health facilities.
†For interviews, two pharmacies that said they would only refer were excluded (n=18). Similarly, two health facilities that said they would wait for laboratory results were excluded (n=22).
‡During simulated visits the median (range) number of medicines dispensed was 2 (2–6), of which 2 (1–5) were antibiotics. During interviews the median (range) number of medicines that would be dispensed by pharmacies was 3 (2–5), of which 2 (2–3) would be antibiotics. The median (range) number of medicines that would be prescribed by health facilities was 3 (1–4), of which 2 (1–4) would be antibiotics.
§Other antimicrobials suggested were: fluonoxazole, tinidazole, secnidazole, metronidazole, gentamicin and ofloxacin.
SD, standard deviation
The median (IQR) medication cost at health facilities was KSh300 (KSh150–400), KSh300 (KSh190–500) at private clinics and zero at government facilities. The cost of ceftriaxone-based regimens was similar to other regimens. Cefixime was available at 65% of pharmacies and 17% of health facilities at a median (IQR) cost of KSh240 (KSh120–300).

**Challenges experienced in STI management**

The majority of interviewees reported difficulties in STI management (70% of pharmacies and 83% of health facilities) including: clients not disclosing important history (36%); inadequate or outdated information on STI management (25%); patient non-adherence (23%); inadequate diagnostic and referral facilities (14%); and language barriers (9%). Interviewees suggested that health provider training (38%), patient education (32%) and community education (18%) would address some of these barriers.

**DISCUSSION**

Our study shows that most men with urethritis present to pharmacies and private clinics for care, that most healthcare providers do not provide nationally recommended or efficacious treatment, and that very few recommend HIV-1 testing. We also found that, unlike government facilities in the study area, most private clinics open for 24 h a day, every day of the week, thus offering the greatest service availability.

Our study achieved a high response rate, but we acknowledge that the results may suffer from some selection bias since not all eligible pharmacies and health facilities consented to participate and only one health worker was interviewed per facility. Additionally, since the study was conducted in two adjacent townships, the results may not be generalisable to the whole of coastal Kenya. Pharmacies reported that they did not suspect any of the simulated clients, and data obtained through simulated visits were largely comparable to interview data. Our interview procedures may therefore have avoided reporting bias. It is worth noting that pharmacies tended to perform better during simulated visits than in interviews, possibly due to a difference in question type. Our sample was relatively small, limiting our ability to identify associations between provider characteristics and treatment practices.

Similar to earlier studies, we found that pharmacies and private clinics provide care for many adults with urethritis. Unlike previous studies in Kenya, we did not find significantly poorer quality of urethritis case management among pharmacies compared with health facilities, except in history-taking. However, this could be due to the small size of our sample or a difference in the definition of quality. Previous studies in Kenya did not assess service availability or specifically document if patients presenting with urethritis were targeted for HIV testing.

Our findings highlight the opportunity for HIV testing, counselling and referral that presents through the frequent STI care-seeking at private clinics and pharmacies. This is particularly relevant considering recent advances in point-of-care testing technology, which could make it more feasible for frontline healthcare providers to recommend and carry out HIV testing in these settings.

We found that most health providers would treat a case of urethritis syndromically and most would include a quinolone as part of the regimen, implying they had some prior exposure to the current syndromic guidelines. However, the guidelines themselves were rarely available on site. Besides availability, we also note with concern that the Kenyan guidelines, as well as the WHO guidelines, still recommend quinolones as a first-line regimen for syndromic treatment despite documented widespread NG resistance. We can only speculate that this failure to revise and disseminate new guidelines is due to a lack of priority given to keeping such documents up to date. Innovative strategies must be devised to ensure prompt updating and dissemination of guidelines. The STI control programme should borrow from other disease programmes that have successfully employed internet and mobile technologies.

Since a majority of interviewees at health facilities and a minority at pharmacies reported being members of a professional association, continuing professional development programmes should aim to use as well as foster professional networks among trainees. As FSWs and MSM are being targeted for HIV prevention in Kenya and frequently seek care at health facilities and pharmacies, recently published guidelines on STI control among these key populations should be included in training programmes for health providers serving in similar settings.

In summary, we found that in an area of high STI burden, most patients with urethritis seek health care from pharmacies and private clinics, and that the treatment provided does not comply with guidelines. In order to reduce the STI and HIV burden, increase HIV testing uptake and enable timely linkage into care, pharmacies and private clinics should be more engaged in HIV/STI prevention programmes. Further research is required to enhance the development, revision and dissemination of guidelines on STI control.

**Key messages**

- In an area of high STI burden, most patients with urethritis seek healthcare from pharmacies and private clinics.
- Pharmacies and private clinics should be more engaged in upscaling HIV/STI prevention programmes.
- Healthcare provider compliance with recommended treatment regimens is low and HIV testing is infrequently recommended.
- Current guidelines still recommend quinolone-based STI regimens, which remain in use in Kenya despite the emergence of resistance.

**Acknowledgements**

We thank the participating health facilities and pharmacies, the Provincial Director of Public Health and Sanitation—Coast and the men who acted as simulated clients. We thank all staff of the HIV Key Populations Studies Cluster of KWTRP-Kilifi, especially Elizabeth Wahome and Jennifer Kanungi. This report was published with permission from KEMRI. This study was presented in part at the 6th INTEREST conference in Mombasa in 2012 (abstract number P-14).

**Contributors**

EJS and SD conceived the study. EJS, SD, ADS, SMG, EVDE, EG, HSO and PMM developed the protocol. PMM, SWM and ANT collected the data. PMM, EJS and SD conceived the study. EJS, SD, ADS, SMG, EVDE, EG, HSO succeeded for HIV prevention in Kenya and frequently seek care at health facilities and pharmacies, recently published guidelines on STI control among these key populations should be included in training programmes for health providers serving in similar settings.

**Funding**

This study received funding from the USA Agency for International Development (USAID) through the International AIDS Vaccine Initiative (IAVI). This work was made possible in part by the support of the American people. The contents are the responsibility of the study authors and do not necessarily reflect the views of USAID or the USA Government. This study also received funding from the Wellcome Trust, through KEMRI-Wellcome Trust Research Programme (KWTRP)-Kilifi core funding (#077092). SWM was funded by the University of Nairobi.

**Competing interests**

None.

**Ethics approval**

Ethical approval was granted by the KEMRI National Ethical Review Committee. Participants provided written informed consent for both study phases. No financial incentive was given for participation. Participant information...
was protected at all times through the use of identification numbers in place of names, and through restriction of access to completed consent forms.

Provenance and peer review  
Not commissioned; externally peer reviewed.

Open Access  
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) licence, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

REFERENCES

Cross-sectional survey of treatment practices for urethritis at pharmacies, private clinics and government health facilities in coastal Kenya: many missed opportunities for HIV prevention

Peter M Mugo, Sarah Duncan, Samuel W Mwaniki, Alexander N Thiong'o, Evanson Gichuru, Haile Selassie Okuku, Elise M van der Elst, Adrian D Smith, Susan M Graham and Eduard J Sanders

Sex Transm Infect 2013 89: 583-589 originally published online May 22, 2013
doi: 10.1136/sextrans-2012-050979

Updated information and services can be found at: http://sti.bmj.com/content/89/7/583

These include:

**Supplementary Material**
Supplementary material can be found at: http://sti.bmj.com/content/suppl/2013/05/22/sextrans-2012-050979.DC1

**References**
This article cites 21 articles, 7 of which you can access for free at: http://sti.bmj.com/content/89/7/583#BIBL

**Open Access**
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections

- Open access (222)
- Drugs: infectious diseases (3182)
- HIV / AIDS (2514)
- HIV infections (2514)
- HIV/AIDS (2514)
- Urethritis (151)
- Vulvovaginal disorders (465)
- Health policy (221)

To request permissions go to: http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to: http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to: http://group.bmj.com/subscribe/